Abeona Therapeutics (ABEO) Competitors

uniQure (NASDAQ:QURE) and Abeona Therapeutics (NASDAQ:ABEO) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, media sentiment, community ranking, institutional ownership, analyst recommendations, profitability, valuation, earnings and risk.

Does the MarketBeat Community favor QURE or ABEO?

uniQure received 122 more outperform votes than Abeona Therapeutics when rated by MarketBeat users. Likewise, 70.70% of users gave uniQure an outperform vote while only 70.36% of users gave Abeona Therapeutics an outperform vote.

Company	Underperform	Outperform
uniQure	Outperform Votes 637 70.70%	Underperform Votes 264 29.30%
Abeona Therapeutics	Outperform Votes 515 70.36%	Underperform Votes 217 29.64%

Which has preferable earnings & valuation, QURE or ABEO?

Abeona Therapeutics has lower revenue, but higher earnings than uniQure. Abeona Therapeutics is trading at a lower price-to-earnings ratio than uniQure, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
uniQure	$15.84M	15.17	-$308.48M	-$6.21	-0.80
Abeona Therapeutics	$3.50M	51.55	-$54.19M	-$3.20	-1.37

Do insiders & institutionals believe in QURE or ABEO?

78.8% of uniQure shares are owned by institutional investors. Comparatively, 80.6% of Abeona Therapeutics shares are owned by institutional investors. 4.7% of uniQure shares are owned by insiders. Comparatively, 5.3% of Abeona Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Is QURE or ABEO more profitable?

Abeona Therapeutics has a net margin of 0.00% compared to Abeona Therapeutics' net margin of -1,562.22%. Abeona Therapeutics' return on equity of -121.60% beat uniQure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
uniQure	-1,562.22%	-121.60%	-34.76%
Abeona Therapeutics	N/A	-543.60%	-78.51%

Which has more risk & volatility, QURE or ABEO?

uniQure has a beta of 0.98, indicating that its stock price is 2% less volatile than the S&P 500. Comparatively, Abeona Therapeutics has a beta of 1.59, indicating that its stock price is 59% more volatile than the S&P 500.

Do analysts prefer QURE or ABEO?

uniQure presently has a consensus target price of $24.75, indicating a potential upside of 400.00%. Abeona Therapeutics has a consensus target price of $21.00, indicating a potential upside of 379.45%. Given Abeona Therapeutics' higher probable upside, equities analysts clearly believe uniQure is more favorable than Abeona Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
uniQure	0 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.71
Abeona Therapeutics	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00

Does the media favor QURE or ABEO?

In the previous week, Abeona Therapeutics had 10 more articles in the media than uniQure. MarketBeat recorded 12 mentions for Abeona Therapeutics and 2 mentions for uniQure. Abeona Therapeutics' average media sentiment score of 1.25 beat uniQure's score of 0.92 indicating that uniQure is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
uniQure	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Abeona Therapeutics	2 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

uniQure and Abeona Therapeutics tied by winning 9 of the 18 factors compared between the two stocks.